|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41,700.00 VND | -0.24% |
|
-0.24% | -20.57% |
| 07-01 | Imexpharm Corporation Announces Cash Dividend for the Year 2025, Payable on July 21, 2026 | CI |
| 06-30 | Imexpharm Corporation Announces Management Appointments | CI |
Projected Income Statement: Imexpharm Corporation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,266,597 | 1,643,707 | 1,994,037 | 2,205,120 | 2,441,085 | 2,659,000 | 2,881,000 |
| Change | - | 29.77% | 21.31% | 10.59% | 10.7% | 8.93% | 8.35% |
| EBITDA | 299,271 | - | 457,049 | 521,703 | - | - | - |
| Change | - | - | - | 14.15% | - | - | - |
| EBIT 1 | 234,475 | 300,992 | 374,407 | 403,285 | 445,003 | 490,000 | 532,000 |
| Change | - | 28.37% | 24.39% | 7.71% | 10.34% | 10.11% | 8.57% |
| Interest Paid | -18,041 | -29,408 | -31,489 | -25,192 | - | - | - |
| Earnings before Tax (EBT) 1 | 238,859 | 301,763 | 377,273 | 404,193 | 446,248 | 493,000 | 535,000 |
| Change | - | 26.34% | 25.02% | 7.14% | 10.4% | 10.48% | 8.52% |
| Net income 1 | 189,095 | 233,964 | 299,556 | 320,862 | 349,138 | 394,000 | 428,000 |
| Change | - | 23.73% | 28.03% | 7.11% | 8.81% | 12.85% | 8.63% |
| Announcement Date | 1/20/22 | 1/17/23 | 1/19/24 | 1/20/25 | 1/20/26 | - | - |
1VND in Million
Estimates
Forecast Balance Sheet: Imexpharm Corporation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - |
| Announcement Date | 1/20/22 | 1/17/23 | 1/19/24 | 1/20/25 | 1/20/26 | - | - |
Estimates
Cash Flow Forecast: Imexpharm Corporation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| CAPEX 1 | 89,685 | 52,857 | 99,353 | 63,530 | 96,771 | 26,879 |
| Change | - | -41.06% | 87.97% | -36.06% | 52.32% | -72.22% |
| Free Cash Flow (FCF) 1 | -18,044 | 211,391 | 274,201 | -69,934 | 145,454 | 380,110 |
| Change | - | 1,271.54% | 29.71% | -125.5% | 307.99% | 161.33% |
| Announcement Date | 3/16/21 | 3/8/22 | 3/24/23 | 3/27/24 | 3/20/25 | 3/24/26 |
1VND in Million
Estimates
Forecast Financial Ratios: Imexpharm Corporation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | 23.63% | - | 22.92% | 23.66% | - | - | - |
| EBIT Margin (%) | - | 18.51% | 18.31% | 18.78% | 18.29% | 18.23% | 18.43% | 18.47% |
| EBT Margin (%) | - | 18.86% | 18.36% | 18.92% | 18.33% | 18.28% | 18.54% | 18.57% |
| Net margin (%) | - | 14.93% | 14.23% | 15.02% | 14.55% | 14.3% | 14.82% | 14.86% |
| FCF margin (%) | - | - | 16.99% | - | - | - | - | - |
| FCF / Net Income (%) | - | - | 119.36% | - | - | - | - | - |
Profitability | ||||||||
| ROA | - | 8.61% | 10.21% | 12.83% | 13.1% | 13.21% | 13.8% | 13.8% |
| ROE | - | 9.32% | 12.65% | 15.06% | 15.04% | - | 16.4% | 16.3% |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - | - | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | 4.17% | 6.04% | - | - | - | - | - |
| CAPEX / EBITDA (%) | - | 17.66% | - | - | - | - | - | - |
| CAPEX / FCF (%) | - | - | 35.58% | - | - | - | - | - |
Items per share | ||||||||
| Cash flow per share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Dividend per Share 1 | - | 649.4 | - | - | 500 | - | 1,000 | 1,000 |
| Change | - | - | - | - | - | - | - | 0% |
| Book Value Per Share 1 | - | 11,651 | 12,368 | 13,535 | 14,175 | - | 16,278 | 17,776 |
| Change | - | - | 6.16% | 9.43% | 4.73% | - | - | 9.2% |
| EPS 1 | - | 1,126 | 1,513 | 1,653 | 1,932 | 1,976 | 2,304 | 2,499 |
| Change | - | - | 34.42% | 9.27% | 16.87% | 2.28% | 16.6% | 8.46% |
| Nbr of stocks (in thousands) | - | 154,011 | 154,011 | 154,007 | 154,009 | 154,009 | 154,009 | 154,009 |
| Announcement Date | - | 1/20/22 | 1/17/23 | 1/19/24 | 1/20/25 | 1/20/26 | - | - |
1VND
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | 18.1x | 16.7x |
| PBR | 2.56x | 2.35x |
| EV / Sales | 2.42x | 2.23x |
| Yield | 2.4% | 2.4% |
EPS & Dividend
Y-o-Y evolution of P/E
Year-on-year evolution of the Yield
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
41,700.00VND
Average target price
56,000.00VND
Spread / Average Target
+34.29%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- IMP Stock
- Financials Imexpharm Corporation
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
